Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer : A Better Choice Based on Data From the Chinese Population
Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Methods: Between February 2019 to December 2021, 95 female hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) patients with MBC received palbociclib combined with AI or fulvestrant were retrospectively analyzed in our center. The primary outcome was progression-free survival (PFS). The objective response rate and clinical benefit rate (CBR) were evaluated. Results: The median follow-up period was 15 months (range from 2 to 37). Palbociclib performed superiorly when applicated in first-and-second line therapy than in later lines (P = .002). Palbociclib combined with AI or fulvestrant had a median PFS of 34 months (95% confidence interval [CI] = 6.87-61.13) and 12 months (95%CI = 7.76-16.24), respectively. Univariate subgroup analysis showed that the previous history of salvage chemotherapy (P = .015) and the presence of liver metastases (P < .001) significantly affected the efficacy of palbociclib. Despite the existence of liver metastases and primary endocrine resistance, which are two independent predictors of poor prognosis, early application of palbociclib in advanced stage can bring further benefits to these two groups of patients, rather than choosing salvage chemotherapy in the first place. Conclusion: Palbociclib combined with endocrine therapy has a favorable efficacy and acceptable toxicity in HR+/HER2- Chinese MBC patients. Better performance can be seen when palbociclib was applicated in the early stage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Technology in cancer research & treatment - 21(2022) vom: 25. Jan., Seite 15330338221132926 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Yusi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
22X328QOC4 |
|---|
| Anmerkungen: |
Date Completed 01.11.2022 Date Revised 18.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/15330338221132926 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348247486 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348247486 | ||
| 003 | DE-627 | ||
| 005 | 20231226035729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/15330338221132926 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348247486 | ||
| 035 | |a (NLM)36310472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Yusi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer |b A Better Choice Based on Data From the Chinese Population |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2022 | ||
| 500 | |a Date Revised 18.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently. Methods: Between February 2019 to December 2021, 95 female hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) patients with MBC received palbociclib combined with AI or fulvestrant were retrospectively analyzed in our center. The primary outcome was progression-free survival (PFS). The objective response rate and clinical benefit rate (CBR) were evaluated. Results: The median follow-up period was 15 months (range from 2 to 37). Palbociclib performed superiorly when applicated in first-and-second line therapy than in later lines (P = .002). Palbociclib combined with AI or fulvestrant had a median PFS of 34 months (95% confidence interval [CI] = 6.87-61.13) and 12 months (95%CI = 7.76-16.24), respectively. Univariate subgroup analysis showed that the previous history of salvage chemotherapy (P = .015) and the presence of liver metastases (P < .001) significantly affected the efficacy of palbociclib. Despite the existence of liver metastases and primary endocrine resistance, which are two independent predictors of poor prognosis, early application of palbociclib in advanced stage can bring further benefits to these two groups of patients, rather than choosing salvage chemotherapy in the first place. Conclusion: Palbociclib combined with endocrine therapy has a favorable efficacy and acceptable toxicity in HR+/HER2- Chinese MBC patients. Better performance can be seen when palbociclib was applicated in the early stage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a China | |
| 650 | 4 | |a endocrine therapy | |
| 650 | 4 | |a first-line | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a palbociclib | |
| 650 | 4 | |a real-world | |
| 650 | 4 | |a retrospective study | |
| 650 | 7 | |a Fulvestrant |2 NLM | |
| 650 | 7 | |a 22X328QOC4 |2 NLM | |
| 650 | 7 | |a palbociclib |2 NLM | |
| 650 | 7 | |a G9ZF61LE7G |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 700 | 1 | |a Chen, Wenlin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shuanglong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Qingmo |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Zhong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Technology in cancer research & treatment |d 2002 |g 21(2022) vom: 25. Jan., Seite 15330338221132926 |w (DE-627)NLM12389655X |x 1533-0338 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g day:25 |g month:01 |g pages:15330338221132926 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/15330338221132926 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |b 25 |c 01 |h 15330338221132926 | ||